AstraZeneca PLC (AZN)
| Market Cap | 227.85B |
| Revenue (ttm) | 56.50B |
| Net Income (ttm) | 8.30B |
| Shares Out | 1.55B |
| EPS (ttm) | 5.31 |
| PE Ratio | 13.97 |
| Forward PE | 15.33 |
| Dividend | $1.54 (2.07%) |
| Ex-Dividend Date | Aug 8, 2025 |
| Volume | 378,597 |
| Open | 73.86 |
| Previous Close | 73.55 |
| Day's Range | 73.75 - 74.31 |
| 52-Week Range | 61.24 - 87.68 |
| Beta | 0.15 |
| Analysts | Strong Buy |
| Price Target | 95.00 (+28.03%) |
| Earnings Date | Jul 29, 2025 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price target is $95.0, which is an increase of 28.03% from the latest price.
News
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
BOSTON and ROLLE, Switzerland , Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a...
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
European drugmakers fall after Trump raises stakes over US drug price cuts
Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping ex...
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...
3 Of The Best SWANs On My Shopping List
Our picks for today are MercadoLibre, Vulcan Materials, and AstraZeneca, with each providing a mix of value and growth. MercadoLibre is Latin America's leading e-commerce and fintech platform with inc...
Accelerating Impact: AstraZeneca and Revna Biosciences Expand Access to Lung Cancer Treatment in Ghana
ACCRA, Ghana--(BUSINESS WIRE)-- #AfricaHealth--The strategic partnership between AstraZeneca and Revna Biosciences is rapidly transforming the landscape of lung cancer care in Ghana. Since the initial...
Healthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressure
AstraZeneca's CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing market with new free offering.
AstraZeneca PLC (AZN) Q2 2025 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET Company Participants Andrew P. Barnett - Head of Investor Relations Aradhana Sarin - CFO & Executive Director Da...
AstraZeneca CEO: Medical innovation in China is surging
"What we have seen in China is really, a substantial return of scientists from the US, but also from the UK and elsewhere, but not because of policy, simply because they could see opportunities in Chi...
AstraZeneca CEO: If you manufacture locally, there's no need to increase prices
CNBC's Sara Eisen talks with AstraZeneca Pascal Soriot CEO to discuss the company's most recent quarter, investment in innovation in the U.S., whether tariffs could impact prices, and much more.
AstraZeneca CEO doubles down on U.S. amid rumors of listing shift
AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was "rapidly transferring manufacturing" across the Atlantic. "This country [the U.S.] wil...
AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook
AstraZeneca Plc AZN on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by do...
AstraZeneca Stock Rises as US, Cancer Drug Growth Lifts Q2 Results
AstraZeneca (AZN) shares are rising in premarket trading Tuesday after the pharma giant beat second-quarter estimates on strong U.S. growth and demand for its cancer drugs.
AstraZeneca results: H1 and Q2 2025
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary H1 2025 % Change Q2 2025 % Change $m Actual CER1 $m Actual CER - Product Sales 26,670 8 10 13,795 11 10 - Alliance Revenue...
AstraZeneca beats second-quarter profit expectations, maintains outlook
AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney disease drugs, but maintained its full-year forecast as pricing pressures and g...
AstraZeneca share price forecast after earnings
AstraZeneca share price held steady this week after the company published strong financial results on Tuesday. AZN stock was trading at 10,790p, a range it has remained in the past few days.
AstraZeneca's eco-friendly version of smoker's lung inhaler gets EU panel backing
A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, the drugmaker said on Friday.
AstraZeneca's immune disorder drug succeeds in late-stage trial
AstraZeneca said on Thursday its experimental therapy gefurulimab met the main goal of a late-stage study looking into improving symptoms of a chronic, autoimmune condition known as generalised myasth...
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...